CR Sanjiu to acquire major assets, strengthening pharmaceutical portfolio

China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) has unveiled its plan to acquire major assets through a substantial purchase report, aiming to bolster its core business and expand its portfolio. The strategic move involves acquiring equity from various Tianjin-based entities affiliated with Tianli, giving CR Sanjiu an increased stake of 28% in Tianli. The acquisitions is funded through cash. The filing also includes legal and auditing reports that were used to evaluate the deal.